November 19, 2019

Register by Nov. 15 for the Best Rate

Please take note that the venue for this event has moved to the Hyatt Regency San Francisco.

Recent relevant Xconomy coverage:

Can AI Tools, $76M Lead BlackThorn to Targeted Psych Drugs?
Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials
With $2M Seed, Perlstein Lab Tests Unorthodox Rare-Disease Plan

3 – 4:00pm

Registration & Networking

4 – 4:30pm

Spinal Cord Injury Therapies Step Forward

Ethan Perlstein – Chief Scientific Officer, Christopher & Dana Reeve Foundation
Abla Creasey – Vice President of Therapeutics and Strategic Infrastructure, California Institute for Regenerative Medicine

Explore the cutting-edge research that could become new therapies for spinal cord injuries and other traumatic neurological damage.

4:30 – 5:00pm

AI Makes Headway Finding New Depression Drugs

Jane Tiller – Chief Medical Officer, BlackThorn Therapeutics
Kristina Burow – Managing Director, ARCH Venture Partners

Depression is a particularly challenging area for drug hunters, but BlackThorn Therapeutics says artificial intelligence, brain imaging, and other tools give it an edge finding and developing new medicines.

5 – 5:30pm

An Immunotherapy Approach to Alzheimer’s

Stephanie Yonker – Vice President of Legal, Alector

Does the immune system hold the key to understanding and treating Alzheimer’s disease? Alector is developing a drug that engages an immune cell in the brain to address neurodegeneration.

5:30 – 6:30pm

Networking Reception

Drinks & hors d’oeuvres

Schedule is subject to change.